tacrolimus

FDA Drug Profile — Tacrolimus, tacrolimus

Drug Details

Generic Name
tacrolimus
Brand Names
Tacrolimus, tacrolimus
Application Number
ANDA200744
Sponsor
E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC
NDC Codes
10
Dosage Forms
OINTMENT, CAPSULE, POWDER
Routes
TOPICAL, ORAL
Active Ingredients
TACROLIMUS

Indications and Usage

1.1 Prophylaxis of Organ Rejection in Kidney, Liver, or Heart Transplant Tacrolimus capsules are indicated for the prophylaxis of organ rejection, in adult patients receiving allogeneic kidney transplant [see Clinical Studies (14.1)], liver transplant [see Clinical Studies (14.2)], and heart transplant [see Clinical Studies (14.3)], and pediatric patients receiving allogeneic liver transplants [see Clinical Studies (14.2)] in combination with other immunosuppressants. Additional pediatric use information is approved for Astellas Pharma US, Inc.’s Prograf (tacrolimus) products. However, due to Astellas Pharma US, Inc.’s marketing exclusivity rights, this drug product is not labeled with that information.